Paraguay Medical Device Registration 2026: Exclusivity Clauses and Ten-Year Channel Control

1. Key takeaways

1. Article 6 inc. b) item 1): the company holding an exclusive representation letter from the manufacturer is recognized as the representative — the exclusivity clause is the highest-ranking criterion for determining the holder, prevailing over every non-exclusive letter that may exist.
2. Article 10: the NSO and the sanitary registration certificate are valid for 10 years and may be renewed consecutively for equal periods — the reach of an authorization letter is therefore measured in decades, not in procurement cycles.
3. The combined effect of Articles 10 and 11: the certificate is valid for 10 years, and renewal must be requested within 120 working days before expiry; if that window is missed, a new registration must be applied for from the beginning, with new fees and a new assessment.
4. Conclusion: whether to grant exclusivity is, in substance, a choice about the channel structure for the next ten years, not a matter of wording in a commercial letter. It should be decided at the level of market strategy, with legal consequences mapped in advance.

2. Legal basis

The three provisions interlock: Article 6 inc. b) decides who may hold, Article 10 decides for how long, and Article 11 decides what happens when the renewal window is handled or mishandled. Reading them together shows why the exclusivity decision made on day one shapes the entire regulatory life of the product in Paraguay.

A further layer is added by the cost of the portfolio over time. Each post-market change under Article 13 requires payment of the corresponding fee, and each change is filed through the holder of the certificate; a manufacturer locked into an exclusive relationship therefore also routes its change portfolio through a single counterparty for a decade. Where the partnership sours, the manufacturer may face a queue of changes that only the holder can submit. This operational dependency — not merely the legal exclusivity — is what companies most often underestimate, and it is the strongest argument for evaluating a license-holding entity independent of the distribution layer before the first certificate is ever filed.

3. Expert insights

Insight one: the legal effect of an exclusivity clause is exclusion, not preference. In the ranking rules, an exclusive letter prevails over all non-exclusive letters. Once signed, the manufacturer cannot obtain a certificate for the same product through another company during the same period. For a manufacturer that hopes to run multiple distributors in parallel and compare their performance, signing an exclusive letter amounts to voluntarily abandoning that model for the duration of the registration relationship. The commitment is not merely commercial: it is embedded in a regulatory ranking that the authority will apply mechanically if two applicants appear.

Insight two: in the non-exclusive scenario, who issues the letter directly becomes the decisive factor. Where there is no exclusivity clause, the criterion is a letter issued directly by the manufacturer, and letters issued by distributors are excluded. The manufacturer can retain control by issuing non-exclusive letters itself, directly to a chosen license-holding entity — a structure that is more flexible than exclusivity because it preserves the ability to redirect the registration through a different controlled entity without breaching an exclusivity promise.

Insight three: the exit cost over the ten-year cycle must be designed in advance. A 10-year certificate validity and a 120-working-day renewal window mean that once the relationship is fixed, a mid-cycle channel change can only be achieved through a change of registration holder (within the Type I changes covering name and address changes) or by applying afresh. The distribution agreement should therefore predefine transfer trigger events, deadlines, and liability for breach, so that an exit negotiated commercially has a regulatory path already mapped.

Insight four: the exclusivity decision interacts with product-level registrations, not just company-level appointments. Because the ranking operates product by product, a manufacturer with a broad portfolio can be locked in for one product line while remaining free on others. This allows graduated strategies — exclusivity where the partner is expected to invest in market development and hospital access, and non-exclusive direct authorization where the product moves on its own clinical merit. Documenting the rationale per product at the time of signing keeps the strategy coherent and defensible if the ranking is ever tested by a competing applicant.

4. Practical recommendations

1. Before signing, compare the two structures in a single table: exclusivity (high channel investment, weaker control) versus non-exclusive direct authorization (stronger control, requires a self-held entity).
2. If the non-exclusive route is chosen, make sure the authorization letter is issued directly by the manufacturer to the intended license-holding entity, without any intermediate issuer.
3. Include in the agreement a transfer-on-demand clause for the registration holder, specifying trigger conditions, processing deadlines, and allocation of fees.
4. Where conditions allow, use a license-holding entity independent of the distributor (for example a manufacturer-owned or designated entity) to decouple the registration certificate from the distribution relationship.
5. Review the authorization structure at each renewal cycle rather than carrying the original decision forward automatically, since market conditions, partner performance, and product status after ten years rarely match the assumptions made at first filing.
6. Record the decision and its rationale in a short internal memorandum approved jointly by the commercial and regulatory functions, so the reasoning behind the exclusivity choice survives personnel changes and can be defended consistently if the structure is ever questioned.

5. Verification checklist

• □ Structural comparison of exclusivity versus non-exclusivity completed
• □ In the non-exclusive scenario the letter is issued directly by the manufacturer
• □ Agreement contains a transfer-on-demand clause for the registration holder
• □ Exit pathways over the 10-year cycle assessed
• □ Renewal window (120 working days) entered into the relationship management calendar

Regulatory information verified as of October 29, 2026.

GRZAN provides medical device registration support in Paraguay for manufacturers, importers, and authorized representatives, covering holder structuring, exclusivity strategy, and transfer planning. Contact info@grzanglobal.com for tailored guidance on this topic.